Skip to main content

Advertisement

SpringerLink
Log in

A Comparison Between Full-COLD PCR/HRM and PCR Sequencing for Detection of Mutations in Exon 9 of PIK3CA in Breast Cancer Patients

  • Published:
Applied Biochemistry and Biotechnology Aims and scope Submit manuscript

Abstract

One of the most common somatic mutations in breast cancer is found in PIK3CA with a prevalence rate of 18–45%. Different variants of this gene are considered as resistance markers for treatment with HER2-targeted medicines. Conventional molecular methods such as Sanger sequencing are not able to detect mutations with low abundance in a mixture of wild-type DNA, especially in the early stages of cancer development. In this study, two methods of co-amplification at lower denaturation temperature PCR (COLD-PCR) and high-resolution melting (HRM) were combined for detection of mutations in exon 9 of PIK3CA; DNA, therefore, was extracted from MCF-7 and BT-474 as mutant and wild-type cell lines respectively. Thereafter, serial dilutions of extracted DNA were used to determine sensitivity of full-COLD PCR/HRM in comparison with conventional PCR sequencing as the gold standard method. Cell line experiments resulted in almost 30 fold increase in sensitivity by use of full-COLD PCR/HRM. In addition, 40 patients with primary breast cancer were investigated with the mentioned methods. As a result of this part of study, four mutations were detected by conventional PCR sequencing including E542K and E545K mutations in three and one samples respectively. Whereas, full-COLD PCR/HRM was able to detect one E542K mutation more than gold standard method which caused the percentage of sensitivity to get improved by 2.5% (10 to 12.5%). Our results clearly demonstrated that full-COLD PCR/HRM could detect lower levels of mutations in wild-type background as a sensitive method with simple and cost-effective procedure; therefore, it can prospectively be used in screening of patients with early-stage breast cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferlay J, Héry C, Autier P, Sankaranarayanan R. (2010) Global burden of breast cancer. Breast cancer epidemiology: Springer; p. 1–19.

  2. Islami F, Torre LA, Drope JM, Ward EM, Jemal A. (2017) Global cancer in women: cancer control priorities. AACR

  3. Abutalib SA, Markman M.(2014) Cancer consult: expertise for clinical practice: John Wiley & Sons

  4. Que, D., Xiao, H., Zhao, B., Zhang, X., Wang, Q., Xiao, H., & Wang, G. (2016). EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. Cancer Biology & Therapy., 17(3), 320–327.

    Article  CAS  Google Scholar 

  5. Yu, B., O’Toole, S. A., & Trent, R. J. (2015). Somatic DNA mutation analysis in targeted therapy of solid tumours. Translational Pediatrics., 4(2), 125–138.

    PubMed  PubMed Central  Google Scholar 

  6. Wang, X. (2014). An exploration of mutation status of cancer genes in breast cancers. Next Generation Sequencing Application, 1, 103.

    Google Scholar 

  7. Samuels, Y., & Velculescu, V. E. (2004). Oncogenic mutations of PIK3CA in human cancers. Cell Cycle, 3(10), 1221–1224.

    Article  CAS  PubMed  Google Scholar 

  8. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science, 304(5670), 554.

    Article  CAS  PubMed  Google Scholar 

  9. Cizkova, M., Dujaric, M., Lehmann-Che, J., Scott, V., Tembo, O., Asselain, B., et al. (2013). Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. British journal of cancer., 108(9), 1807–1809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Goel S, Krop IE. PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum. Oxford University Press; 2016.

  11. Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2009). Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Annals of Oncology., 21(2), 255–262.

    Article  PubMed  Google Scholar 

  12. Harlé, A., Lion, M., Lozano, N., Husson, M., Harter, V., Genin, P., et al. (2013). Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria. Oncology reports., 29(3), 1043–1052.

    Article  CAS  PubMed  Google Scholar 

  13. Milbury, C. A., Li, J., Liu, P., & Makrigiorgos, G. M. (2011). COLD-PCR: improving the sensitivity of molecular diagnostics assays. Expert review of molecular diagnostics., 11(2), 159–169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Li, J., Wang, L., Mamon, H., Kulke, M. H., Berbeco, R., & Makrigiorgos, G. M. (2008). Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nature medicine., 14(5), 579–584.

    Article  CAS  PubMed  Google Scholar 

  15. Merlo, L. M., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006). Cancer as an evolutionary and ecological process. Nature Reviews Cancer., 6(12), 924–935.

    Article  CAS  PubMed  Google Scholar 

  16. Milbury, C. A., Li, J., & Makrigiorgos, G. M. (2009). COLD-PCR–enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. Clinical chemistry., 55(12), 2130–2143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kwiatkowska, J., Wigowska-Sowinska, J., Napierala, D., Slomski, R., & Kwiatkowski, D. J. (1999). Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis. New England Journal of Medicine., 340(9), 703–707.

    Article  CAS  PubMed  Google Scholar 

  18. Li, J., Milbury, C. A., Li, C., & Makrigiorgos, G. M. (2009). Two-round coamplification at lower denaturation temperature–PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. Human mutation., 30(11), 1583–1590.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Yates, L. R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., et al. (2015). Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nature medicine., 21(7), 751–759.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Newton, C., Graham, A., Heptinstall, L., Powell, S., Summers, C., Kalsheker, N., et al. (1989). Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic acids research., 17(7), 2503–2516.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991). Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science, 254(5037), 1497–1500.

    Article  CAS  PubMed  Google Scholar 

  22. Dominguez, P. L., & Kolodney, M. S. (2005). Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens. Oncogene, 24(45), 6830–6834.

    Article  CAS  PubMed  Google Scholar 

  23. Milbury, C. A., Li, J., & Makrigiorgos, G. M. (2009). PCR-based methods for the enrichment of minority alleles and mutations. Clinical chemistry., 55(4), 632–640.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Matsuda, K. (2017). Chapter two-PCR-based detection methods for single-nucleotide polymorphism or mutation: real-time PCR and its substantial contribution toward technological refinement. Advances in Clinical Chemistry., 80, 45–72.

    Article  CAS  PubMed  Google Scholar 

  25. Li J, Makrigiorgos GM.(2009) COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Portland Press Limited

  26. Lipsky, R. H., Mazzanti, C. M., Rudolph, J. G., Xu, K., Vyas, G., Bozak, D., Radel, M. Q., & Goldman, D. (2001). DNA melting analysis for detection of single nucleotide polymorphisms. Clinical Chemistry., 47(4), 635–644.

    CAS  PubMed  Google Scholar 

  27. Liew, M., Pryor, R., Palais, R., Meadows, C., Erali, M., Lyon, E., & Wittwer, C. (2004). Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clinical chemistry., 50(7), 11`56–11`64.

    Article  CAS  Google Scholar 

  28. Palais, B. (2007). Quantitative heteroduplex analysis. Clinical Chemistry, 53(6), 1001–1003.

    Article  CAS  PubMed  Google Scholar 

  29. Sobin, L. H., & Fleming, I. D. (1997). TNM classification of malignant tumors, (1997). Cancer: Interdisciplinary International Journal of the American Cancer Society., 80(9), 1803–1804.

    Article  CAS  Google Scholar 

  30. Sanger, F., Nicklen, S., & Coulson, A. R. (1977). DNA sequencing with chain-terminating inhibitors. Proceedings of the national academy of sciences., 74(12), 5463–5467.

    Article  CAS  Google Scholar 

  31. Kristensen, L. S., Daugaard, I. L., Christensen, M., Hamilton-Dutoit, S., Hager, H., & Hansen, L. L. (2010). Increased sensitivity of KRAS mutation detection by high-resolution melting analysis of COLD-PCR products. Human mutation., 31(12), 1366–1373.

    Article  CAS  PubMed  Google Scholar 

  32. Boisselier, B., Marie, Y., Labussière, M., Ciccarino, P., Desestret, V., Wang, X., Capelle, L., Delattre, J. Y., & Sanson, M. (2010). COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Human mutation., 31(12), 1360–1365.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran

    Safoura Ghalamkari, Farinaz Khosravian, Hamidreza Mianesaz, Mohammad Kazemi & Mansoor Salehi

  2. Medical Genetic Center of Genome, Isfahan, Iran

    Safoura Ghalamkari, Farinaz Khosravian, Mohammad Kazemi & Mansoor Salehi

  3. Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

    Mohaddeseh Behjati

  4. Cancer Prevention Research Center, Isfahan University of Medical Science, Isfahan, Iran

    Sayyed Mohammadreza Hakimian

Authors
  1. Safoura Ghalamkari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farinaz Khosravian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hamidreza Mianesaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Kazemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohaddeseh Behjati
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sayyed Mohammadreza Hakimian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mansoor Salehi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mansoor Salehi.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghalamkari, S., Khosravian, F., Mianesaz, H. et al. A Comparison Between Full-COLD PCR/HRM and PCR Sequencing for Detection of Mutations in Exon 9 of PIK3CA in Breast Cancer Patients. Appl Biochem Biotechnol 187, 975–983 (2019). https://doi.org/10.1007/s12010-018-2859-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12010-018-2859-3

Keywords

Search

Navigation